TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05679596

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ketone monoester (R)-3-hydroxybutyl (R)-3- hydroxybutyrate
Description: Provided twice a day between meals.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: carbohydrate-fat placebo (fructose, corn and canola oil 50:50 ratio)
Description: Provided twice a day between meals.
Study: NCT05216913

Intervention type: BEHAVIORAL
Intervention: Lifestyle modification
Description: Could include all/some of the following: weight loss, increased physical activity, smoking cessation and reduction in alcohol intake

Intervention type: DRUG
Intervention: Cardiovascular Agents, Other
Description: Could include all/some of the following: statins, antihypertensives, diabetic medication, levothyroxine

Intervention type: OTHER
Intervention: QRISK 3 Score
Description: Could include a combination of lifestyle measures and/or cardiovascular agents as described above
Study: NCT05753007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD)
Description: Custom-formulated full-spectrum solution high in cannabidiol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution
Study: NCT06269718

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: swallowing therapy
Description: oral exercises, tongue movement, and compensatory techniques, swallowing maneuvers and food modifications, will be performed by an experienced speech and language therapist during intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: swallowing therapy
Description: oral exercises, tongue movement, and compensatory techniques, swallowing maneuvers and food modifications, will be performed by an experienced speech and language therapist during intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IOPI therapy
Description: tongue muscle strengthening and endurance exercises by using 15-min IOPI biofeedback program. The biofeedback will be 50%-60% of maximal strength. (total 1 hour/session for 10 sessions)
Study: NCT05004350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: oral hard capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: oral hard capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Combination of:~irinotecan ( also known as: Camptosar, Camptothecin-11 and CPT-11) intravenous infusion, folinic acid (also known as: 5-formyl tetrahydrofolic acid and leucovorin) intravenous infusion, and 5-FU (also known as; fluorouracil) intravenous bolus/intravenous infusion
Study: NCT05952960

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Open Label Placebo + Rationale

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Open Label Placebo + Rationale

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Open Label Placebo + Rationale
Study: NCT05955430

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Description: It consists of strengthening exercises and gradual walking. The lower limb strengthening exercises are individualized and progressive for each patient for twelve weeks. There will be eight face-to-face sessions over four weeks. And then the patient will continue with those exercises for eight more weeks. In addition, they must perform twelve weeks of progressive walking until they are walking at least 30 minutes, 5 days a week at a moderate intensity (defined as moderate shortness of breath while walking).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic exercise
Description: It consists of strengthening exercises and gradual walking. The lower limb strengthening exercises are individualized and progressive for each patient for twelve weeks. There will be eight face-to-face sessions over four weeks. And then the patient will continue with those exercises for eight more weeks. In addition, they must perform twelve weeks of progressive walking until they are walking at least 30 minutes, 5 days a week at a moderate intensity (defined as moderate shortness of breath while walking).
Study: NCT06291350

Intervention type: OTHER
Intervention: periodontal examination
Description: Characterization of the periodontal and digestive microbiota (metagenomic analysis), assessment of clinical attachment loss and alveolysis

Intervention type: OTHER
Intervention: periodontal examination
Description: Characterization of the periodontal and digestive microbiota (metagenomic analysis), assessment of clinical attachment loss and alveolysis
Study: NCT04714983

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNX-2440
Description: DNX-2440 is a replication competent oncolytic adenovirus expressing human OX40 ligand.
Study: NCT06214624

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Two types of exercise interventions
Description: * HIIT. 3 times/week. This consists of a 4x4 HIIT (preferably in treadmill), 4 intervals of 4min at high intensity (85-95% HRmax) and 3 intervals of 3min of active resting at \~70% HRmax in between. All sessions including 10 min of warming-up and 10min of cooling down, resulting in 45min sessions. The first 2 weeks will progress from moderate-intensity training to HIIT for a better adaptation and acceptability of the program.~* HIIT + resistance. 3 times/week. The aerobic part consists of a 3x4 HIIT (preferably in treadmill), 3 intervals of 4min at high intensity (85-95% HRmax) and 2 intervals of 3min of active resting (\~70% HRmax) in between. The resistance part consists of 2 series of an 8-exercise circuit (combination of upper and lower body exercises using elastic bands and body weight) with a ratio of 20sec of effort - 40sec of resting. Sessions will have 5min of warming up in the treadmill and 5min of cooling down walking in the gym, comprising a total of 45min sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Two types of exercise interventions
Description: * HIIT. 3 times/week. This consists of a 4x4 HIIT (preferably in treadmill), 4 intervals of 4min at high intensity (85-95% HRmax) and 3 intervals of 3min of active resting at \~70% HRmax in between. All sessions including 10 min of warming-up and 10min of cooling down, resulting in 45min sessions. The first 2 weeks will progress from moderate-intensity training to HIIT for a better adaptation and acceptability of the program.~* HIIT + resistance. 3 times/week. The aerobic part consists of a 3x4 HIIT (preferably in treadmill), 3 intervals of 4min at high intensity (85-95% HRmax) and 2 intervals of 3min of active resting (\~70% HRmax) in between. The resistance part consists of 2 series of an 8-exercise circuit (combination of upper and lower body exercises using elastic bands and body weight) with a ratio of 20sec of effort - 40sec of resting. Sessions will have 5min of warming up in the treadmill and 5min of cooling down walking in the gym, comprising a total of 45min sessions.
Study: NCT05371938

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Volar locking plate
Description: Volar locking plate is the intervention

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: external fixation
Description: surgery with external fixation
Study: NCT06216197

Intervention type: DRUG
Group type: OTHER
Intervention: FENT group
Description: Group FENT, consisting of 29 patients, underwent a saddle block with hyperbaric bupivacaine (2.5 ml) combined with fentanyl (0.5 ml; 25 μg).

Intervention type: DRUG
Group type: OTHER
Intervention: DEX group
Description: The DEX Group, consisting of 29 patients, received 2.5 ml of hyperbaric bupivacaine mixed with dexmedetomidine (10 μg; 0.5 ml).
Study: NCT04883567

Intervention type: DIAGNOSTIC_TEST
Intervention: The use of artificial intelligence system Cerebro
Description: The artificial intelligence system Cerebro would be used during OGD
Study: NCT06165523

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: 340 mL plain tap water consumed immediately following glycogen depleting exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flavored Kefir
Description: 320 mL kefir consumed immediately following glycogen depleting exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flavored Milk
Description: 240 mL flavored milk consumed immediately following glycogen depleting exercise
Study: NCT06047990

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryobiopsy catheter
Description: Comparison of endobiliary forceps biopsy and cryobiopsy of biliary stenosis during percutaneous transhepatic drainage.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryobiopsy catheter
Description: Comparison of endobiliary forceps biopsy and cryobiopsy of biliary stenosis during percutaneous transhepatic drainage.
Study: NCT04714983

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNX-2440
Description: DNX-2440 is a replication competent oncolytic adenovirus expressing human OX40 ligand.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNX-2440
Description: DNX-2440 is a replication competent oncolytic adenovirus expressing human OX40 ligand.
Study: NCT05918965

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcutaneous electrical vagal neurostimulation
Description: daily for 12 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous electrical vagal neurostimulation
Description: daily for 12 weeks
Study: NCT05117749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saffron 100
Description: to Mild and Moderate UC patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saffron 100
Description: to Mild and Moderate UC patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saffron 50
Description: to Mild and Moderate UC patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saffron 50
Description: to Mild and Moderate UC patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: to Mild and Moderate UC patients
Study: NCT05918965

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcutaneous electrical vagal neurostimulation
Description: daily for 12 weeks
Study: NCT06552845

Intervention type: DIAGNOSTIC_TEST
Intervention: LGE-MRI Scan
Description: Participants will receive LGE-MRI scan before catheter ablation and 3 months after catheter ablation
Study: NCT05679960

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Urine PolypDx machine Versus Colonoscopy
Description: 1. Urine samples of the participants in each group will be analyzed to check for preidentified metabolites that signified colorectal cancer~2. Colonoscopy, which is the gold standard for colorectal cancer diagnosis/screening will be performed on all the participants positive for metabolites signifying CRC on Urine PolypDx machine in all the groups

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Urine PolypDx machine Versus Colonoscopy
Description: 1. Urine samples of the participants in each group will be analyzed to check for preidentified metabolites that signified colorectal cancer~2. Colonoscopy, which is the gold standard for colorectal cancer diagnosis/screening will be performed on all the participants positive for metabolites signifying CRC on Urine PolypDx machine in all the groups

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Urine PolypDx machine Versus Colonoscopy
Description: 1. Urine samples of the participants in each group will be analyzed to check for preidentified metabolites that signified colorectal cancer~2. Colonoscopy, which is the gold standard for colorectal cancer diagnosis/screening will be performed on all the participants positive for metabolites signifying CRC on Urine PolypDx machine in all the groups
Study: NCT05047133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: TXA to be given at time of diagnosis in the emergency department (ED) in treatment group and at time of operation for both groups

Intervention type: DRUG
Group type: OTHER
Intervention: Tranexamic acid
Description: TXA to be given at time of diagnosis in the emergency department (ED) in treatment group and at time of operation for both groups
Study: NCT06214442

Intervention type: OTHER
Intervention: Evaluations of the mechanical properties of the achilles tendon in different phases of the menstrual cycle
Description: Monitoring assessments to verify the effect of different phases of the menstrual cycle on the neuromechanical properties of the Achilles tendon.
Study: NCT05117749

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: to Mild and Moderate UC patients
Study: NCT06214442

Intervention type: OTHER
Intervention: Evaluations of the mechanical properties of the achilles tendon in different phases of the menstrual cycle
Description: Monitoring assessments to verify the effect of different phases of the menstrual cycle on the neuromechanical properties of the Achilles tendon.

Intervention type: OTHER
Intervention: Evaluations of the mechanical properties of the achilles tendon in different phases of the menstrual cycle
Description: Monitoring assessments to verify the effect of different phases of the menstrual cycle on the neuromechanical properties of the Achilles tendon.
Study: NCT05186012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-1252
Description: APG-1252 administered via intravenous infusion for 30 minutes weekly (Day 1, 8, 15, 22).Every 28 days as a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-1252
Description: APG-1252 administered via intravenous infusion for 30 minutes weekly (Day 1, 8, 15, 22).Every 28 days as a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide 30mg orally BIW. Every 28 days as a cycle.
Study: NCT05484427

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Replacement of the regullar meeting with diabetologist by remote communication only
Study: NCT05771805

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation with task oriented training
Description: VNS Group will receive non-invasive vagus nerve stimulation at left auricle of ear for 30 mins during the task-oriented training. Subjects will receive protocol 3 days per week for 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Task oriented training
Description: Task oriented group will receive task oriented training and placebo effect with vagus nerve stimulator.
Study: NCT05201482

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SightPlus
Description: SightPlus is a head-mounted, augmented reality low vision aid. SightPlus enables people with a visual impairment to use their remaining vision to see more clearly up close and at a distance. SightPlus is commercially available, non-invasive, CE marked, and a MHRA approved class 1 medical device.
Study: NCT06335069

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI-46 PET/CT and 68Ga-FAPI-46 PET/MRI
Description: All participating patients will undergo an additional 68Ga-FAPI- 46 PET/CT and 68Ga-FAPI-46 PET/MRI scan prior to their breast cancer treatment.
Study: NCT04525235

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: phenotyping cocktail
Description: A single dose of a cocktail of phenotyping probe drugs (caffeine, tolbutamide, omeprazole, dextromethorphan, midazolam and digoxin) will be administered together with standard dose rifampicin and 40 mg/kg rifampicin, respectively. Blood samples will be taken to assess phenotyping metrics of the cocktail agents and rifampicin pharmacokinetic parameters. The effect of high and standard dose rifampicin on the phenotyping metrics of the cocktail agents will be compared by using the bioequivalence approach

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: phenotyping cocktail
Description: A single dose of a cocktail of phenotyping probe drugs (caffeine, tolbutamide, omeprazole, dextromethorphan, midazolam and digoxin) will be administered together with standard dose rifampicin and 40 mg/kg rifampicin, respectively. Blood samples will be taken to assess phenotyping metrics of the cocktail agents and rifampicin pharmacokinetic parameters. The effect of high and standard dose rifampicin on the phenotyping metrics of the cocktail agents will be compared by using the bioequivalence approach

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampicin
Description: A single dose of a cocktail of phenotyping probe drugs (caffeine, tolbutamide, omeprazole, dextromethorphan, midazolam and digoxin) will be administered together with standard dose rifampicin and 40 mg/kg rifampicin, respectively. Blood samples will be taken to assess phenotyping metrics of the cocktail agents and rifampicin pharmacokinetic parameters. The effect of high and standard dose rifampicin on the phenotyping metrics of the cocktail agents will be compared by using the bioequivalence approach

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rifampicin
Description: A single dose of a cocktail of phenotyping probe drugs (caffeine, tolbutamide, omeprazole, dextromethorphan, midazolam and digoxin) will be administered together with standard dose rifampicin and 40 mg/kg rifampicin, respectively. Blood samples will be taken to assess phenotyping metrics of the cocktail agents and rifampicin pharmacokinetic parameters. The effect of high and standard dose rifampicin on the phenotyping metrics of the cocktail agents will be compared by using the bioequivalence approach
Study: NCT05571735

Intervention type: BIOLOGICAL
Intervention: Pfizer-BioNTech COVID-19 vaccine
Description: Pfizer-BioNTech COVID-19 vaccine, Messenger RNA (mRNA) based vaccine encoding the viral spike glycoprotein (S) Formulation: Frozen concentrate before dilution with 0.9% sodium chloride solution for injection Route of Administration: Intramuscular (IM) Dosing regimen: Two doses (0.3 mL per dose) (at least 3 weeks apart)
Study: NCT05843591

Intervention type: BEHAVIORAL
Intervention: aerobic exercise or Tai Chi Chuan interventions
Description: 8-week aerobic exercise (AE group), 8-week Tai Chi Chuan training (TCC group)
Study: NCT05571735

Intervention type: BIOLOGICAL
Intervention: Pfizer-BioNTech COVID-19 vaccine
Description: Pfizer-BioNTech COVID-19 vaccine, Messenger RNA (mRNA) based vaccine encoding the viral spike glycoprotein (S) Formulation: Frozen concentrate before dilution with 0.9% sodium chloride solution for injection Route of Administration: Intramuscular (IM) Dosing regimen: Two doses (0.3 mL per dose) (at least 3 weeks apart)

Intervention type: BIOLOGICAL
Intervention: AstraZeneca vaccine
Description: AstraZeneca vaccine, a replication-deficient simian adenoviral vector expressing the spike (S) protein of SARS-CoV-2 Formulation: Aqueous solution for injection Route of Administration: Intramuscular (IM) Dosing regimen: Two doses (0.5 mL per dose) (at least 12 weeks apart)

Intervention type: BIOLOGICAL
Intervention: AstraZeneca vaccine
Description: AstraZeneca vaccine, a replication-deficient simian adenoviral vector expressing the spike (S) protein of SARS-CoV-2 Formulation: Aqueous solution for injection Route of Administration: Intramuscular (IM) Dosing regimen: Two doses (0.5 mL per dose) (at least 12 weeks apart)

Intervention type: BIOLOGICAL
Intervention: Janssen Ad26.COV2.S COVID-19 vaccine
Description: Janssen Ad26.COV2.S COVID-19 vaccine, recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike protein.~Formulation: Suspension for injection Route of Administration: Intramuscular (IM) Dosing regimen single dose (0.5 mL)

Intervention type: BIOLOGICAL
Intervention: Janssen Ad26.COV2.S COVID-19 vaccine
Description: Janssen Ad26.COV2.S COVID-19 vaccine, recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike protein.~Formulation: Suspension for injection Route of Administration: Intramuscular (IM) Dosing regimen single dose (0.5 mL)
Study: NCT05843591

Intervention type: BEHAVIORAL
Intervention: aerobic exercise or Tai Chi Chuan interventions
Description: 8-week aerobic exercise (AE group), 8-week Tai Chi Chuan training (TCC group)

Intervention type: BEHAVIORAL
Intervention: aerobic exercise or Tai Chi Chuan interventions
Description: 8-week aerobic exercise (AE group), 8-week Tai Chi Chuan training (TCC group)
Study: NCT05751265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5Fu
Description: Participants will receive 5-FU, 2.4 g/m2，bid，d1-d14，q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel injection
Description: Participants will receive paclitaxel 135 mg/m2 ivgtt q2w or 175mg/m2 q3w
Study: NCT05425303

Intervention type: DIAGNOSTIC_TEST
Intervention: Exposure to risk for injury
Description: Athletes will be examined in the preseason stage and will be monitored during the competitive season.
Study: NCT06092112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD-801
Description: The subjects with advanced HCC will be treated by 100 μg CD-801 through the hepatic artery injection at two-week intervals. The dosing interval will be adjusted based on subject tolerability, safety, and efficacy. For example, it may be adjusted to administer the medication once every three weeks or four weeks.
Study: NCT05188599

Intervention type: DIAGNOSTIC_TEST
Intervention: İsokinetic assessment
Description: Isokinetic assessments of hip flexor and extensor muscle strength and proprioception wiill be performed
Study: NCT05968716

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social needs screening protocol
Description: Pediatric hospital ward stakeholders will develop and implement a social needs screening protocol designed to screen families of hospitalized children for social risk factors and then provide resources to address their social needs. The intervention will consist of the protocol that is developed and implemented.
Study: NCT06302920

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kinesiotape
Description: Lymphatic correction technique
Study: NCT06107101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: 100mg of mepolizumab every 4 weeks subcutaneously for 6 months
Study: NCT05495958

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Vitamin D eye drop
Description: 25 Microgram/cc or 1000 IU

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical placebo eye drop
Description: The same-shape packed drop without vitamin D
Study: NCT05276427

Intervention type: OTHER
Intervention: Non Clinical procedure
Description: Non clinical procedure- Informed consent completion and interview session
Study: NCT06078891

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG vaccine
Description: Three intra-dermal vaccinations over a period of one year.